Form 4: Avidity Biosciences CEO Sarah Boyce Executes Stock Option and Sells Shares Under 10b5-1 Plan

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On July 9, 2024, Sarah Boyce, the President and CEO of Avidity Biosciences, exercised stock options to acquire 28,000 shares of common stock at a price of $1.24 per share.
• Simultaneously, Boyce sold 28,000 shares of common stock at a weighted-average price of $39.9315 per share, with individual sales ranging from $38.70 to $40.52.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 9, 2023.
• Following these transactions, Boyce directly owns 205,043 shares of Avidity Biosciences common stock and holds options for 489,015 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. The CEO retains a significant stake in the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
• The CEO's continued holding of 205,043 shares and options for 489,015 shares suggests ongoing confidence in the company.

Negatives

• The sale of shares by the CEO, even under a 10b5-1 plan, could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although the 10b5-1 plan mitigates this concern.
• Market reaction to the CEO's stock sales could create short-term price volatility.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's future prospects.

Stakeholder Impact

• Shareholders may react to the CEO's stock sale, although the 10b5-1 plan should reassure them that it was pre-planned.
• The company's reputation could be affected depending on how the market interprets the transactions.

Key Dates